HUTCHMED (China) Limited (AIM:HCM)
214.00
-5.00 (-2.28%)
Feb 12, 2026, 4:35 PM GMT
HUTCHMED (China) Employees
HUTCHMED (China) had 1,780 employees as of June 30, 2025.
Employees
1,780
Change
n/a
Growth
n/a
Revenue / Employee
246.93K GBP
Profits / Employee
191.45K GBP
Market Cap
1.88B
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Jun 30, 2025 | 1,780 | - | - |
| Dec 31, 2024 | 1,811 | -177 | -8.90% |
| Dec 31, 2023 | 1,988 | -37 | -1.83% |
| Dec 31, 2022 | 2,025 | 265 | 15.06% |
| Dec 31, 2021 | 1,760 | 480 | 37.50% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| Haleon | 24,561 |
| Hikma Pharmaceuticals | 9,500 |
| Allergy Therapeutics | 584 |
| Animalcare Group | 201 |
| ECO Animal Health Group | 200 |
| Shield Therapeutics | 63 |
| Venture Life Group | 43 |
| Chill Brands Group | 9 |
HUTCHMED (China) News
- 6 days ago - HUTCHMED to Announce 2025 Final Results - GlobeNewsWire
- 10 days ago - HUTCHMED (China) Ltd (HCM) Stock Price Down 3.53% on Feb 2 - GuruFocus
- 4 weeks ago - HUTCHMED Highlights Publication of Phase III SACHI Results in The Lancet - GlobeNewsWire
- 5 weeks ago - Positive China Trial Data Moves HUTCHMED Closer To Rare Blood Disorder Drug Filing In 2026 - Benzinga
- 5 weeks ago - Positive China Trial Data Moves HUTCHMED Closer To Rare Blood Disorder Drug Filing In 2026 - Benzinga
- 5 weeks ago - HUTCHMED's ESLIM-02 Trial Of Sovleplenib In Warm Autoimmune Hemolytic Anemia Meets Key Goal - Nasdaq
- 5 weeks ago - HUTCHMED's Sovleplenib Reaches Phase III Goal In Warm Autoimmune Hemolytic Anemia Trial In China - Nasdaq
- 5 weeks ago - HCM's Sovleplenib Trial Achieves Key Milestone in Treating Autoimmune Hemolytic Anemia - GuruFocus